Apures Co's revenue for the
six
months ended in Dec. 2023 was ₩658.9 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was ₩658.9 Mil.
Apures Co's Revenue per Share for the
six
months ended in Dec. 2023 was ₩16.91.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was ₩16.91.
Warning Sign:
Apures Co Ltd revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Apures Co was -21.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 7.80% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 0.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 10 years, Apures Co's highest 3-Year average Revenue per Share Growth Rate was 8.80% per year. The lowest was -32.90% per year. And the median was -1.30% per year.
Apures Co Revenue Historical Data
The historical data trend for Apures Co's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Apures Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apures Co's Revenue Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Apures Co's Revenue distribution charts can be found below:
* The bar in red indicates where Apures Co's Revenue falls into.
Apures Co Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
For stock reported annually, GuruFocus uses latest annual data as the TTM data. Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was ₩658.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apures Co (XKRX:149300) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Apures Co Revenue Related Terms
Thank you for viewing the detailed overview of Apures Co's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Apures Co Ltd is a South Korea based company engaged in the development of transgenic animals to support bio heterogeneous long-term commercialization and new drug efficacy research. It has focused its research capabilities on developing transgenic mini pigs based on gene editing technology and somatic cell nuclear transfer technology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XKRX:149300 has been successfully added to your 